1.
训练集与验证集临床特征对比
Clinical characteristics of the training cohort and validation cohort
| Training cohort (n=70) |
Validation cohort (n=70) |
P | |
| Age(year) | 0.86 | ||
| <41 | 31 | 30 | |
| ≥41 | 39 | 40 | |
| Gender | 0.84 | ||
| Male | 54 | 53 | |
| Female | 16 | 17 | |
| Histology | 0.65 | ||
| Differentiated keratinising |
0 | 0 | |
| Differentiated non-keratinising |
2 | 3 | |
| Undifferentiated non-keratinising |
68 | 67 | |
| T stage | 0.96 | ||
| T1 | 2 | 3 | |
| T2 | 12 | 11 | |
| T3 | 35 | 34 | |
| T4 | 21 | 22 | |
| N stage | 0.98 | ||
| N0 | 7 | 6 | |
| N1 | 20 | 21 | |
| N2 | 33 | 34 | |
| N3 | 10 | 9 | |
| TNM Stage | 0.49 | ||
| Ⅲ | 44 | 40 | |
| Ⅳ | 26 | 30 | |
| EBV DNA(copies/mL) | 0.73 | ||
| <4000 | 35 | 37 | |
| ≥4000 | 35 | 33 | |
| VCA-IgA | 0.72 | ||
| <1:160 | 23 | 25 | |
| ≥1:160 | 47 | 45 | |
| EA-IgA | 0.50 | ||
| <1:20 | 29 | 33 | |
| ≥1:20 | 41 | 37 | |
| CRP(mg/L) | 0.74 | ||
| <2.0 | 37 | 35 | |
| ≥2.0 | 33 | 35 | |
| LDH(U/L) | 0.39 | ||
| <184 | 42 | 37 | |
| ≥184 | 28 | 33 | |
| NWR | 0.74 | ||
| <0.65 | 38 | 36 | |
| ≥0.65 | 32 | 34 | |
| NLR | 0.61 | ||
| <2.8 | 40 | 37 | |
| ≥2.8 | 30 | 33 | |
| HGB,x109/L | 0.61 | ||
| <140 | 28 | 31 | |
| ≥140 | 42 | 39 | |
| PLT,x109/L | 0.61 | ||
| <232.7 | 40 | 43 | |
| ≥232.7 | 30 | 27 | |
| ALB/ALP | 0.50 | ||
| <0.58 | 41 | 37 | |
| ≥0.58 | 29 | 33 | |
| Concurrent chemoradiotherapy |
0.58 | ||
| Yes | 64 | 62 | |
| No | 6 | 8 | |
| Induction chemotherapy | 0.71 | ||
| Yes | 19 | 21 | |
| No | 51 | 49 |